金河生物(002688.SZ)擬6.65億元新建年產5.2萬噸獸藥級高效金黴素1000噸鹽酸金黴素原料藥項目
格隆匯 9 月 23日丨金河生物(002688.SZ)公佈,2020年9月23日,公司第五屆董事會第六次會議審議通過了《關於新建年產52000噸獸藥級高效金黴素1000噸鹽酸金黴素原料藥項目的議案》。項目預計總投資約6.65億元。
項目名稱:年產52000噸獸藥級高效金黴素1000噸鹽酸金黴素原料藥項目。建設內容:該項目總佔地面積141.45畝,總建築面積為79967m2,總構築物面積為7970m2,包括髮酵車間、提取車間、實驗中心、檢驗中心、辦公樓、倒班宿舍以及配套建設公用設施、輔助設施和附屬設施等。建設規模:項目建成後實現年產獸藥級高效金黴素52000噸,鹽酸金黴素1000噸。
根據可研報告估算,該項目財務內部收益率税後39.46%,税前45.86%;項目投資回收期税後3.50年,税前3.16年(不含建設期)。該項目投產後,銷售收入估算年總收入為92800.00萬元,平均利潤總額為21087.51萬元。
該項目建設符合國家的產業政策,符合公司堅持主營業務發展,鞏固和提升主營業務核心競爭力的戰略佈局。公司現有金黴素年綜合產能5.3萬噸,生產設施具備年產1000噸鹽酸金黴素和3000噸土黴素鹼的提取能力,新項目的建設有利於公司產品系列的完善和結構的調整。可持續降低生產成本,降耗增效明顯。另一方面,該項目建設週期短,生產週期短,投資風險較低,投產後公司產品有較強的應變和競爭能力,可以保持較強的市場抗風險能力,提升公司業務規模,有利於提高公司未來主營業務盈利能力,增強綜合實力,符合公司長遠發展的戰略佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.